Jazz Pharma (JAZZ) Raises FY12 Outlook
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $254.28 +2.24%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Jazz Pharma (Nasdaq: JAZZ) raised its FY12 EPS guidance to $4.25-$4.40 on sales of $500-$510 million. The Street is currently looking for FY12 EPS of $4.45 on sales of $516.75 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
- ATRenew Inc (RERE) Tops Q2 EPS by 8c ; Offers Guidance
Create E-mail Alert Related Categories
GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
